Massachusetts 2025-2026 Regular Session

Massachusetts House Bill H1205 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	1 of 1
2	2	HOUSE DOCKET, NO. 2249 FILED ON: 1/15/2025
3	3	HOUSE . . . . . . . . . . . . . . . No. 1205
4	4	The Commonwealth of Massachusetts
5	5	_________________
6	6	PRESENTED BY:
7	7	Bradley H. Jones, Jr.
8	8	_________________
9	9	To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General
10	10	Court assembled:
11	11	The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:
12	12	An Act establishing a commission to study the promotion of preferred pharmacy networks.
13	13	_______________
14	14	PETITION OF:
15	15	NAME:DISTRICT/ADDRESS :DATE ADDED:Bradley H. Jones, Jr.20th Middlesex1/15/2025Paul K. Frost7th Worcester1/31/2025Todd M. Smola1st Hampden3/10/2025Hannah Kane11th Worcester1/31/2025 1 of 2
16	16	HOUSE DOCKET, NO. 2249 FILED ON: 1/15/2025
17	17	HOUSE . . . . . . . . . . . . . . . No. 1205
18	18	By Representative Jones of North Reading, a petition (accompanied by bill, House, No. 1205) of
19	19	Bradley H. Jones, Jr. and others relative to establishing a commission (including members of the
20	20	General Court) to study the promotion of preferred pharmacy networks where insurers can
21	21	negotiate lower drug prices. Financial Services.
22	22	[SIMILAR MATTER FILED IN PREVIOUS SESSION
23	23	SEE HOUSE, NO. 1053 OF 2023-2024.]
24	24	The Commonwealth of Massachusetts
25	25	_______________
26	26	In the One Hundred and Ninety-Fourth General Court
27	27	(2025-2026)
28	28	_______________
29	29	An Act establishing a commission to study the promotion of preferred pharmacy networks.
30	30	Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority
31	31	of the same, as follows:
32	32	1 Notwithstanding any general or special law to the contrary, there shall be a commission
33	33	2to study the implementation of preferred pharmacy networks, whereby health insurers steer
34	34	3consumers to lower-cost “preferred” pharmacies where insurers can negotiate lower drug prices.
35	35	4 The commission shall consist of the house and senate chairs of the joint committee on
36	36	5health care financing, who shall serve as the co-chairs; one member to be appointed by the
37	37	6speaker of the house of representatives; one member to be appointed by the president of the
38	38	7senate; one member to be appointed by the house minority leader; one member to be appointed
39	39	8by the senate minority leader; the director of the health policy commission or a designee; the 2 of 2
40	40	9commissioner of the department of public health or a designee; and the executive director of the
41	41	10center for health information and analysis or a designee.
42	42	11 The commission shall study the feasibility of implementing preferred pharmacy networks
43	43	12and make recommendations based on a cost-benefit analysis of such networks. The commission
44	44	13shall provide estimates of projected savings in prescription drug costs from implementing such
45	45	14networks.
46	46	15 The commission shall submit its report and findings, along with any recommendations
47	47	16and drafted legislation, to the house and senate committees on ways and means, the joint
48	48	17committee on health care financing, and the clerks of the house of representatives and senate
49	49	18within 12 months of the passage of this act.